Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:15 PM
Ignite Modification Date:
2025-12-24 @ 4:15 PM
NCT ID:
NCT01579266
Eligibility Criteria:
* INCLUSION CRITERIA:
* Inclusion criteria for patients with WC and age and handedness-matched HVs:
* Subjects must be at least 18 years of age.
* Subjects must be willing to be videotaped while writing.
* Subjects must have regular hand function with the ability to write without an assistive device
EXCLUSION CRITERIA:
* Patients with WC:
* Botulinum toxin (BTX) administration within 3 months of participation.
* Unable to provide consent.
* Patients taking oral medications for WC including muscle relaxants or other centrally-active medications such as antidepressants which may enhance tremors.
* Medical conditions that affect hand function, such as stroke, nerve entrapment, tremor, parkinsonism, chorea, ataxia affecting the dominant hand.
* HVs:
* Unable to provide consent.
* Healthy volunteers taking oral medications that may affect motor function such as muscle relaxants or centrally-active medications including medications for psychiatric conditions like antidepressants and antipsychotics.
* Healthy volunteers with abnormal hand function including medical conditions that may influence hand function, e.g., strokes, nerve entrapments, tremor, parkinsonism, chorea, ataxia and psychiatric conditions (such as psychosis and depression) affecting the dominant hand.
* Have history of hand surgery and or hand trauma.
* Have abnormal findings on medical history and physical exam.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
99 Years
Study:
NCT01579266
Study Brief:
Protocol Section:
NCT01579266